ADMA Biologics Faces Securities Fraud Class Action Over Growth Claims

The litigation, captioned Mazzarino v. ADMA Biologics, Inc., et al., centers on claims that the company misled shareholders regarding its 2025 financial results. According to the complaint, ADMA reported 20% annual growth by inducing distributors to stockpile its flagship immune globulin product, ASCENIV, through rebates and extended payment terms rather than organic market demand.

This legal challenge follows a March 2026 report by Culper Research, which alleged that the company’s reliance on these tactics masked an actual 3% revenue decline. The disclosure triggered a severe market reaction, with ADMA shares dropping 16.6% on March 24, 2026, and experiencing further volatility following a subsequent analyst downgrade. Bleichmar Fonti & Auld LLP, the firm representing the class, asserts that these actions violated sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Affected shareholders are encouraged to review their legal options before the upcoming August deadline.